Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 334

1.

RH-Temperature Stability Diagram of the Dihydrate, β-Anhydrate, and α-Anhydrate Forms of Crystalline Trehalose.

Allan M, Chamberlain MC, Mauer LJ.

J Food Sci. 2019 Jun;84(6):1465-1476. doi: 10.1111/1750-3841.14591. Epub 2019 May 1.

PMID:
31042816
2.

Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group.

Arvold ND, Armstrong TS, Warren KE, Chang SM, DeAngelis LM, Blakeley J, Chamberlain MC, Dunbar E, Loong HH, Macdonald DR, Reardon DA, Vogelbaum MA, Yuan Y, Weller M, van den Bent M, Wen PY.

Neuro Oncol. 2018 Jun 18;20(7):897-906. doi: 10.1093/neuonc/noy056.

3.

Leptomeningeal metastasis.

Taillibert S, Chamberlain MC.

Handb Clin Neurol. 2018;149:169-204. doi: 10.1016/B978-0-12-811161-1.00013-X. Review.

PMID:
29307353
4.

Immunochemotherapy, the New Standard of Care for Primary CNS Lymphoma: However, Which One?

Chamberlain MC.

J Clin Oncol. 2016 Nov 20;34(33):4056-4057. doi: 10.1200/JCO.2016.68.9018. Epub 2016 Oct 31. No abstract available.

PMID:
29236597
5.

Cerebrospinal Fluid Dissemination and Neoplastic Meningitis in Primary Brain Tumors.

Chowdhary S, Damlo S, Chamberlain MC.

Cancer Control. 2017 Jan;24(1):S1-S16.

PMID:
28557973
6.

Nivolumab for patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series.

Chamberlain MC, Kim BT.

J Neurooncol. 2017 Jul;133(3):561-569. doi: 10.1007/s11060-017-2466-0. Epub 2017 May 12.

PMID:
28500559
7.

Response assessment in medulloblastoma and leptomeningeal seeding tumors: recommendations from the Response Assessment in Pediatric Neuro-Oncology committee.

Warren KE, Vezina G, Poussaint TY, Warmuth-Metz M, Chamberlain MC, Packer RJ, Brandes AA, Reiss M, Goldman S, Fisher MJ, Pollack IF, Prados MD, Wen PY, Chang SM, Dufour C, Zurakowski D, Kortmann RD, Kieran MW.

Neuro Oncol. 2018 Jan 10;20(1):13-23. doi: 10.1093/neuonc/nox087. Review.

8.

Salvage therapy with bendamustine for temozolomide refractory recurrent anaplastic gliomas: a prospective phase II trial.

Chamberlain MC, Colman H, Kim BT, Raizer J.

J Neurooncol. 2017 Feb;131(3):507-516. doi: 10.1007/s11060-016-2241-7. Epub 2017 Feb 16.

PMID:
28204914
9.

Neoplastic Meningitis Due to Lung, Breast, and Melanoma Metastases.

Le Rhun E, Taillibert S, Chamberlain MC.

Cancer Control. 2017 Jan;24(1):22-32. Review.

PMID:
28178709
10.

Posterior Reversible Encephalopathy Syndrome Associated With Dose-adjusted EPOCH (Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin) Chemotherapy.

Floeter AE, Patel A, Tran M, Chamberlain MC, Hendrie PC, Gopal AK, Cassaday RD.

Clin Lymphoma Myeloma Leuk. 2017 Apr;17(4):225-230. doi: 10.1016/j.clml.2016.12.004. Epub 2017 Jan 10.

PMID:
28169156
11.

Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma.

Chamberlain MC, Baik CS, Gadi VK, Bhatia S, Chow LQ.

Neuro Oncol. 2017 Jan;19(1):i1-i24. doi: 10.1093/neuonc/now197. Review.

12.

Neuro-oncology: a selected review of ASCO 2016 abstracts.

Chamberlain MC.

CNS Oncol. 2016 Oct;5(4):193-8. doi: 10.2217/cns-2016-0036. Epub 2016 Sep 12.

13.

Chemotherapy-Related Neurotoxicity.

Taillibert S, Le Rhun E, Chamberlain MC.

Curr Neurol Neurosci Rep. 2016 Sep;16(9):81. doi: 10.1007/s11910-016-0686-x. Review.

PMID:
27443648
14.

Treatment for Patients With Newly Diagnosed Glioblastoma.

Chamberlain MC.

JAMA. 2016 Jun 7;315(21):2348. doi: 10.1001/jama.2016.1844. No abstract available.

PMID:
27272590
15.

Anaplastic astrocytoma.

Grimm SA, Chamberlain MC.

CNS Oncol. 2016 Jul;5(3):145-57. doi: 10.2217/cns-2016-0002. Epub 2016 May 27. Review.

16.

A selected review of abstracts from the 20th Annual Meeting of the Society for Neuro-Oncology (SNO).

Chamberlain MC.

CNS Oncol. 2016 Jul;5(3):115-9. doi: 10.2217/cns-2016-0014. Epub 2016 May 27.

17.

Systemic therapy for recurrent meningioma.

Le Rhun E, Taillibert S, Chamberlain MC.

Expert Rev Neurother. 2016 Aug;16(8):889-901. doi: 10.1080/14737175.2016.1184087. Epub 2016 May 19.

PMID:
27123883
18.

Targetable Lung Cancer Brain Metastases: Improved Outcome.

Chamberlain MC.

J Clin Oncol. 2016 Jul 1;34(19):2315. doi: 10.1200/JCO.2016.66.9465. Epub 2016 Apr 25. No abstract available.

PMID:
27114601
19.

Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas.

Albert NL, Weller M, Suchorska B, Galldiks N, Soffietti R, Kim MM, la Fougère C, Pope W, Law I, Arbizu J, Chamberlain MC, Vogelbaum M, Ellingson BM, Tonn JC.

Neuro Oncol. 2016 Sep;18(9):1199-208. doi: 10.1093/neuonc/now058. Epub 2016 Apr 21. Review.

20.

What Lessons Are Imparted From SWOG S9005 for Recurrent Meningioma?

Chamberlain MC.

J Clin Oncol. 2016 May 20;34(15):1825-6. doi: 10.1200/JCO.2015.66.2288. Epub 2016 Mar 14. No abstract available.

PMID:
26976413
21.

Standard chemoradiation for glioblastoma results in progressive brain volume loss.

Chamberlain MC.

Neurology. 2016 Mar 8;86(10):979. doi: 10.1212/01.wnl.0000481823.96137.39. No abstract available.

PMID:
26952303
22.

Flow-Related Aneurysm within Glioblastoma: A Case Report and Review of Literature.

Ene CI, Nerva JD, McGrath L, Flanagan ME, Chamberlain MC, Silbergeld DL.

World Neurosurg. 2016 May;89:729.e1-6. doi: 10.1016/j.wneu.2016.01.068. Epub 2016 Feb 4. Review.

PMID:
26851739
23.

Current Management of Adult Diffuse Infiltrative Low Grade Gliomas.

Le Rhun E, Taillibert S, Chamberlain MC.

Curr Neurol Neurosci Rep. 2016 Feb;16(2):15. doi: 10.1007/s11910-015-0615-4.

PMID:
26750130
24.

Co-existence of glioblastoma and cerebral aneurysm.

Chamberlain MC.

CNS Oncol. 2016;5(1):9-10. doi: 10.2217/cns.15.44. Epub 2015 Dec 18. No abstract available.

25.

Recurrent ganglioglioma in adults treated with BRAF inhibitors.

Chamberlain MC.

CNS Oncol. 2016;5(1):27-9. doi: 10.2217/cns.15.40. Epub 2015 Dec 18.

26.

Similar Trials With Differing Outcomes: Reconciliation in Glioblastoma.

Chamberlain MC.

J Clin Oncol. 2016 Jan 20;34(3):291-2. doi: 10.1200/JCO.2015.64.1746. Epub 2015 Nov 30. No abstract available.

PMID:
26628477
27.

Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas.

Schiff D, Desjardins A, Cloughesy T, Mikkelsen T, Glantz M, Chamberlain MC, Reardon DA, Wen PY.

Cancer. 2016 Feb 15;122(4):582-7. doi: 10.1002/cncr.29798. Epub 2015 Nov 20.

28.

High-dose cytarabine salvage therapy for recurrent primary CNS lymphoma.

Chamberlain MC.

J Neurooncol. 2016 Feb;126(3):545-50. doi: 10.1007/s11060-015-1994-8. Epub 2015 Nov 13.

PMID:
26563190
29.

Tumor treating fields: a new standard treatment for glioblastoma?

Taillibert S, Le Rhun E, Chamberlain MC.

Curr Opin Neurol. 2015 Dec;28(6):659-64. doi: 10.1097/WCO.0000000000000250. Review.

PMID:
26551239
30.

Bevacizumab and other novel therapies for recurrent oligodendroglial tumors.

Grimm SA, Chamberlain MC.

CNS Oncol. 2015;4(5):333-9. doi: 10.2217/cns.15.27. Epub 2015 Oct 28. Review.

31.

Patterns of response to crizotinib in recurrent glioblastoma according to ALK and MET molecular profile in two patients.

Le Rhun E, Chamberlain MC, Zairi F, Delmaire C, Idbaih A, Renaud F, Maurage CA, Grégoire V.

CNS Oncol. 2015;4(6):381-6. doi: 10.2217/cns.15.30. Epub 2015 Oct 26.

32.

Central Nervous System Cancers, Version 1.2015.

Nabors LB, Portnow J, Ammirati M, Baehring J, Brem H, Brown P, Butowski N, Chamberlain MC, Fenstermaker RA, Friedman A, Gilbert MR, Hattangadi-Gluth J, Holdhoff M, Junck L, Kaley T, Lawson R, Loeffler JS, Lovely MP, Moots PL, Mrugala MM, Newton HB, Parney I, Raizer JJ, Recht L, Shonka N, Shrieve DC, Sills AK Jr, Swinnen LJ, Tran D, Tran N, Vrionis FD, Weiss S, Wen PY, McMillian N, Engh AM.

J Natl Compr Canc Netw. 2015 Oct;13(10):1191-202.

PMID:
26483059
33.

Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma.

Chamberlain MC.

Neurology. 2015 Sep 22;85(12):1090. doi: 10.1212/WNL.0000000000001988. No abstract available.

PMID:
26391415
34.

Prognostic significance of relative 1p/19q codeletion in oligodendroglial tumors.

Chamberlain MC, Born D.

J Neurooncol. 2015 Nov;125(2):249-51. doi: 10.1007/s11060-015-1906-y. Epub 2015 Sep 4.

PMID:
26341371
35.

Targeted Therapy for Brain Metastases in EGFR-Mutated and ALK-Rearranged Non-Small-Cell Lung Cancer.

Baik CS, Chamberlain MC, Chow LQ.

J Thorac Oncol. 2015 Sep;10(9):1268-1278. doi: 10.1097/JTO.0000000000000615. Review.

36.

Complications related to the use of an intraventricular access device for the treatment of leptomeningeal metastases from solid tumor: a single centre experience in 112 patients.

Zairi F, Le Rhun E, Bertrand N, Boulanger T, Taillibert S, Aboukais R, Assaker R, Chamberlain MC.

J Neurooncol. 2015 Sep;124(2):317-23. doi: 10.1007/s11060-015-1842-x. Epub 2015 Jun 13.

PMID:
26070555
37.

Treatment of meningioma, including in cases with no further surgical or radiotherapy options.

Chamberlain MC.

Oncology (Williston Park). 2015 May;29(5):369-71. No abstract available.

38.

Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.

Chamberlain MC, Sanson M.

Neurology. 2015 May 12;84(19):2007. doi: 10.1212/WNL.0000000000001625. No abstract available.

PMID:
25964481
39.

Anaplastic glioma: current treatment and management.

Le Rhun E, Taillibert S, Chamberlain MC.

Expert Rev Neurother. 2015 Jun;15(6):601-20. doi: 10.1586/14737175.2015.1042455. Epub 2015 May 2. Review.

PMID:
25936680
40.

A selected review of abstracts from the 19th annual meeting of the Society for Neuro-Oncology.

Chamberlain MC.

CNS Oncol. 2015;4(3):125-9. doi: 10.2217/cns.15.6. Epub 2015 Apr 23. Review.

41.

Does Hippocampal-Avoidance Whole-Brain Radiotherapy for Brain Metastases Meaningfully Change Current Practice?

Chamberlain MC.

J Clin Oncol. 2015 Jun 10;33(17):1985. doi: 10.1200/JCO.2014.60.4769. Epub 2015 Apr 20. No abstract available.

PMID:
25897152
42.

Prolonged Response and Restoration of Functional Independence with Bevacizumab plus Vinorelbine as Third-Line Treatment for Breast Cancer-Related Leptomeningeal Metastases.

Le Rhun E, Taillibert S, Boulanger T, Zairi F, Bonneterre J, Chamberlain MC.

Case Rep Oncol. 2015 Feb 12;8(1):72-7. doi: 10.1159/000375293. eCollection 2015 Jan-Apr.

43.

The future of high-grade glioma: Where we are and where are we going.

Le Rhun E, Rhun EL, Taillibert S, Chamberlain MC.

Surg Neurol Int. 2015 Feb 13;6(Suppl 1):S9-S44. doi: 10.4103/2152-7806.151331. eCollection 2015. Erratum in: Surg Neurol Int. 2015 Mar 05;6:37. Rhun, Emilie Le [corrected to Le Rhun, Emilie].

44.

High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma.

Chamberlain MC.

Neurology. 2015 Feb 17;84(7):758-9. doi: 10.1212/01.wnl.0000461333.55612.f2. No abstract available.

PMID:
25688152
45.

Neoplastic myelopathies.

Chamberlain MC.

Continuum (Minneap Minn). 2015 Feb;21(1 Spinal Cord Disorders):132-45. doi: 10.1212/01.CON.0000461089.02113.1b. Review.

PMID:
25651222
46.
47.

Salvage therapy with lomustine for temozolomide refractory recurrent anaplastic astrocytoma: a retrospective study.

Chamberlain MC.

J Neurooncol. 2015 Apr;122(2):329-38. doi: 10.1007/s11060-014-1714-9. Epub 2015 Jan 7.

PMID:
25563816
48.

O6-methylguanine-DNA methyltransferase activity is associated with response to alkylating agent therapy and with MGMT promoter methylation in glioblastoma and anaplastic glioma.

Bobola MS, Alnoor M, Chen JY, Kolstoe DD, Silbergeld DL, Rostomily RC, Blank A, Chamberlain MC, Silber JR.

BBA Clin. 2015 Jun 1;3:1-10.

49.

Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study.

Ahluwalia MS, Xie H, Dahiya S, Hashemi-Sadraei N, Schiff D, Fisher PG, Chamberlain MC, Pannullo S, Newton HB, Brewer C, Wood L, Prayson R, Elson P, Peereboom DM.

J Neurooncol. 2015 Mar;122(1):111-9. doi: 10.1007/s11060-014-1684-y. Epub 2014 Dec 23.

PMID:
25534576
50.

Glioblastoma in the elderly.

Chamberlain MC.

Cancer Treat Res. 2015;163:159-70. doi: 10.1007/978-3-319-12048-5_10. Review.

PMID:
25468231

Supplemental Content

Loading ...
Support Center